etodolac has been researched along with Rheumatoid Arthritis in 46 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
| Excerpt | Relevance | Reference |
|---|---|---|
| "9 years) with rheumatoid arthritis (RA) (10 with normal renal function and 3 with moderate renal insufficiency) participated in a 5-day study to assess the effects of etodolac on renal function and the necessity of dose adjustment." | 9.09 | [Investigation of plasma levels of etodolac and urine PGE2 in patients with rheumatoid arthritis]. ( Aoki, A; Chiba, J; Hagiya, N; Ishigatsubo, Y; Kawai, T; Matsunaga, K; Motoji, K; Nagaoka, S; Nakamura, M; Senuma, A; Tani, K; Yawata, M, 1999) |
| "We compared the longterm efficacy and safety of 2 dosages of etodolac with that of ibuprofen in the treatment of active rheumatoid arthritis (RA)." | 9.08 | Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. ( Neustadt, DH, 1997) |
| "The efficacy and safety of etodolac and piroxicam in patients with active rheumatoid arthritis were compared." | 9.08 | Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. Etodolac Study 326 Rheumatoid Arthritis Investigators Group. ( Lightfoot, R, 1997) |
| "A study was carried out to compare the efficacy and tolerability of etodolac and piroxicam in patients with rheumatoid arthritis." | 9.07 | Double-blind comparison of etodolac and piroxicam in patients with rheumatoid arthritis. ( Schattenkirchner, M, 1991) |
| "MTX (10 mg) was administered intramuscularly in the absence and presence of steady state levels of etodolac in 19 patients with rheumatoid arthritis." | 9.07 | Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis. ( Alric, R; Anaya, JM; Bologna, C; Bressolle, F; Cocciglio, M; Dropsy, R; Fabre, D; Sany, J, 1994) |
| "Etodolac was compared with aspirin and placebo for efficacy and safety, and a minimum effective dose was established in 264 patients with adult-onset, active rheumatoid arthritis." | 9.06 | Minimum effective dose of etodolac for the treatment of rheumatoid arthritis. ( Epstein, C; Jacob, G; Kennedy, J; Messina, M; Mullane, J; Sanda, M, 1986) |
| "A 14-day double-blind clinical study was conducted on 16 patients with clinically active rheumatoid arthritis to compare the effects of etodolac (600 mg daily) and diclofenac (150 mg daily)." | 9.06 | Etodolac versus diclofenac: double-blind cross-over study in rheumatoid arthritis. ( Bazzichi, L; Ciompi, ML; Marotta, G; Puccetti, L; Remorini, E, 1989) |
| "The therapeutic efficacy and upper gastrointestinal side effects of a twice daily dose of 300 mg etodolac and 500 mg naproxen were compared in 30 hospital out-patients with active rheumatoid arthritis." | 9.06 | Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy. ( McLaughlin, S; Russell, RI; Sturrock, RD; Taha, AS, 1989) |
| "Etodolac, a nonsteroidal anti-inflammatory drug (NSAID) of the pyranocarboxylic acid family, has been tested in international clinical trials as a therapy for rheumatoid arthritis (RA)." | 9.06 | International experience with etodolac therapy for rheumatoid arthritis: an interim report of comparative efficacy. ( Briancon, D, 1989) |
| "The synthesis of gastric and duodenal mucosal prostaglandin E2, prostaglandin I2, and thromboxane B2 during a 60 minute incubation of biopsy specimens, the degree of endoscopic and histological damage, and the anti-inflammatory response were all studied after a four week, double blind study of therapeutic doses of two non-steroidal anti-inflammatory drugs, naproxen and etodolac, received by 27 patients with active rheumatoid arthritis (13 receiving naproxen, 14 etodolac)." | 9.06 | Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis. ( Holland, PJ; Kelly, RW; McLaughlin, S; Russell, RI; Sturrock, RD; Taha, AS, 1990) |
| "Etodolac and naproxen were compared using a randomized double-blind, crossover method in 39 hospital out-patients with rheumatoid arthritis." | 9.06 | Etodolac versus naproxen in rheumatoid arthritis: a double-blind crossover study. ( Waltham-Weeks, CD, 1987) |
| "Etodolac, aspirin, and placebo were evaluated for efficacy and safety in 20 patients with adult-onset active rheumatoid arthritis who entered a 12-week, double-blind, parallel-group study divided into drug titration and maintenance periods and preceded by a two-week washout period." | 9.05 | Twelve-week study of etodolac, aspirin, and placebo in patients with rheumatoid arthritis. ( Concepción, R; del Toro, RA, 1983) |
| "Etodolac, aspirin, and placebo were evaluated for efficacy and safety in 18 patients with adult-onset, active rheumatoid arthritis." | 9.05 | Etodolac, aspirin, and placebo in patients with rheumatoid arthritis: a 12-week study. ( Edwards, W, 1983) |
| "The effectiveness of etodolac in the treatment of patients with osteoarthritis (OA) and with rheumatoid arthritis (RA) has been well documented in controlled clinical trials." | 8.79 | Clinical performance of etodolac in patients with osteoarthritis and rheumatoid arthritis. ( Veys, EM, 1994) |
| "Short and longterm safety and efficacy of etodolac in a wide range of dosages in patients with rheumatoid arthritis (RA) are summarized." | 8.79 | Low dose etodolac in rheumatoid arthritis: a review of early studies. ( Spencer-Green, G, 1997) |
| "Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) effective in the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis, and in the alleviation of postoperative pain." | 8.78 | Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. ( Balfour, JA; Buckley, MM, 1991) |
| "A meta-analysis was done with the data from two studies that provided the first efficacy and safety results for the new sustained-release (SR) formulation of etodolac versus established nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis (RA)." | 8.78 | Meta-analysis of two double-blind comparative studies with the sustained-release form of etodolac in rheumatoid arthritis. ( Porzio, F, 1993) |
| " The pharmacokinetic study in human volunteers showed that the selected etodolac-loaded cubosomes enhanced the bioavailability of etodolac as compared to the oral capsules (266." | 5.46 | Etodolac transdermal cubosomes for the treatment of rheumatoid arthritis: ex vivo permeation and in vivo pharmacokinetic studies. ( Kamel, AO; Mahmoud, AA; Salah, S, 2017) |
| "This is the first case report of membranous nephropathy in a patient with early-stage rheumatoid arthritis treated with the relatively selective cyclooxygenase-2 inhibitor, etodolac." | 5.34 | Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. ( Aoyama, M; Deji, N; Kashiwagi, A; Kikuchi, K; Nishio, Y; Sakaguchi, M; Sugimoto, T; Uzu, T, 2007) |
| "9 years) with rheumatoid arthritis (RA) (10 with normal renal function and 3 with moderate renal insufficiency) participated in a 5-day study to assess the effects of etodolac on renal function and the necessity of dose adjustment." | 5.09 | [Investigation of plasma levels of etodolac and urine PGE2 in patients with rheumatoid arthritis]. ( Aoki, A; Chiba, J; Hagiya, N; Ishigatsubo, Y; Kawai, T; Matsunaga, K; Motoji, K; Nagaoka, S; Nakamura, M; Senuma, A; Tani, K; Yawata, M, 1999) |
| "The efficacy and safety of etodolac and piroxicam in patients with active rheumatoid arthritis were compared." | 5.08 | Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. Etodolac Study 326 Rheumatoid Arthritis Investigators Group. ( Lightfoot, R, 1997) |
| "We compared the longterm efficacy and safety of 2 dosages of etodolac with that of ibuprofen in the treatment of active rheumatoid arthritis (RA)." | 5.08 | Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. ( Neustadt, DH, 1997) |
| "MTX (10 mg) was administered intramuscularly in the absence and presence of steady state levels of etodolac in 19 patients with rheumatoid arthritis." | 5.07 | Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis. ( Alric, R; Anaya, JM; Bologna, C; Bressolle, F; Cocciglio, M; Dropsy, R; Fabre, D; Sany, J, 1994) |
| "A study was carried out to compare the efficacy and tolerability of etodolac and piroxicam in patients with rheumatoid arthritis." | 5.07 | Double-blind comparison of etodolac and piroxicam in patients with rheumatoid arthritis. ( Schattenkirchner, M, 1991) |
| "The safety profile of a new sustained-release (SR) form of etodolac was evaluated in 539 young and elderly patients with osteoarthritis or rheumatoid arthritis." | 5.07 | The safety profile of sustained-release etodolac. ( Schattenkirchner, M, 1993) |
| "The synthesis of gastric and duodenal mucosal prostaglandin E2, prostaglandin I2, and thromboxane B2 during a 60 minute incubation of biopsy specimens, the degree of endoscopic and histological damage, and the anti-inflammatory response were all studied after a four week, double blind study of therapeutic doses of two non-steroidal anti-inflammatory drugs, naproxen and etodolac, received by 27 patients with active rheumatoid arthritis (13 receiving naproxen, 14 etodolac)." | 5.06 | Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis. ( Holland, PJ; Kelly, RW; McLaughlin, S; Russell, RI; Sturrock, RD; Taha, AS, 1990) |
| "Etodolac was compared with aspirin and placebo for efficacy and safety, and a minimum effective dose was established in 264 patients with adult-onset, active rheumatoid arthritis." | 5.06 | Minimum effective dose of etodolac for the treatment of rheumatoid arthritis. ( Epstein, C; Jacob, G; Kennedy, J; Messina, M; Mullane, J; Sanda, M, 1986) |
| "Etodolac, a nonsteroidal anti-inflammatory drug (NSAID) of the pyranocarboxylic acid family, has been tested in international clinical trials as a therapy for rheumatoid arthritis (RA)." | 5.06 | International experience with etodolac therapy for rheumatoid arthritis: an interim report of comparative efficacy. ( Briancon, D, 1989) |
| "Etodolac has been shown to have a favorable safety profile in short-term and long-term studies in both osteoarthritis (OA) and rheumatoid arthritis (RA)." | 5.06 | Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins. ( Russell, RI, 1990) |
| "A 14-day double-blind clinical study was conducted on 16 patients with clinically active rheumatoid arthritis to compare the effects of etodolac (600 mg daily) and diclofenac (150 mg daily)." | 5.06 | Etodolac versus diclofenac: double-blind cross-over study in rheumatoid arthritis. ( Bazzichi, L; Ciompi, ML; Marotta, G; Puccetti, L; Remorini, E, 1989) |
| "The therapeutic efficacy and upper gastrointestinal side effects of a twice daily dose of 300 mg etodolac and 500 mg naproxen were compared in 30 hospital out-patients with active rheumatoid arthritis." | 5.06 | Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy. ( McLaughlin, S; Russell, RI; Sturrock, RD; Taha, AS, 1989) |
| " In this study, the effect on gastrointestinal blood loss of high-dose etodolac, 300 and 500 mg bid, versus piroxicam at its normal therapeutic dose of 20 mg qd, was investigated by the 51Cr method in 23 men with osteo- or rheumatoid arthritis." | 5.06 | Gastrointestinal blood loss in arthritic patients receiving chronic dosing with etodolac and piroxicam. ( Garg, DC; Jallad, NS; Mullane, JF; Perdomo, CS; Salom, IL; Sanda, M; Weidler, DJ, 1986) |
| "Etodolac and naproxen were compared using a randomized double-blind, crossover method in 39 hospital out-patients with rheumatoid arthritis." | 5.06 | Etodolac versus naproxen in rheumatoid arthritis: a double-blind crossover study. ( Waltham-Weeks, CD, 1987) |
| "Etodolac, aspirin, and placebo were evaluated for efficacy and safety in 20 patients with adult-onset active rheumatoid arthritis who entered a 12-week, double-blind, parallel-group study divided into drug titration and maintenance periods and preceded by a two-week washout period." | 5.05 | Twelve-week study of etodolac, aspirin, and placebo in patients with rheumatoid arthritis. ( Concepción, R; del Toro, RA, 1983) |
| "Etodolac, aspirin, and placebo were evaluated for efficacy and safety in 18 patients with adult-onset, active rheumatoid arthritis." | 5.05 | Etodolac, aspirin, and placebo in patients with rheumatoid arthritis: a 12-week study. ( Edwards, W, 1983) |
| "The effectiveness of etodolac in the treatment of patients with osteoarthritis (OA) and with rheumatoid arthritis (RA) has been well documented in controlled clinical trials." | 4.79 | Clinical performance of etodolac in patients with osteoarthritis and rheumatoid arthritis. ( Veys, EM, 1994) |
| "Short and longterm safety and efficacy of etodolac in a wide range of dosages in patients with rheumatoid arthritis (RA) are summarized." | 4.79 | Low dose etodolac in rheumatoid arthritis: a review of early studies. ( Spencer-Green, G, 1997) |
| "Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) effective in the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis, and in the alleviation of postoperative pain." | 4.78 | Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. ( Balfour, JA; Buckley, MM, 1991) |
| "A meta-analysis was done with the data from two studies that provided the first efficacy and safety results for the new sustained-release (SR) formulation of etodolac versus established nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis (RA)." | 4.78 | Meta-analysis of two double-blind comparative studies with the sustained-release form of etodolac in rheumatoid arthritis. ( Porzio, F, 1993) |
| "Etodolac has previously been reported to have an excellent safety profile." | 3.76 | A global safety evaluation of etodolac. ( Karbowski, A, 1989) |
| " Data from patients 65 years and older with osteoarthritis or rheumatoid arthritis show that etodolac is as well tolerated in elderly as in younger patients." | 3.69 | Safety profile of etodolac in the elderly population. ( Bacon, PA, 1994) |
| "Etodolac is a new nonsteroidal anti-inflammatory drug (NSAID) that has shown a favorable safety profile in clinical trials in osteoarthritis (OA) and rheumatoid arthritis (RA)." | 3.68 | Global safety of etodolac: reports from worldwide postmarketing surveillance studies. ( Serni, U, 1990) |
| " A total of 1276 adverse reactions (AR) were reported during the study, and fewer than half of these were related to study treatment." | 2.67 | Large-scale open trials with etodolac (Lodine) in France: an assessment of safety. ( Benhamou, CL, 1990) |
| "Etodolac is a new nonsteroidal anti-inflammatory drug (NSAID) with potent analgesic and antiarthritic properties." | 2.67 | An overview of the efficacy of etodolac in arthritic disorders. ( Bacon, PA, 1990) |
| " Although ketorolac, which is now available in oral form, is an effective analgesic, its long-term use is limited by a high incidence of gastrointestinal toxicity." | 2.39 | A review of selected newer nonsteroidal anti-inflammatory drugs. ( Amadio, P; Cummings, DM, 1994) |
| "Etodolac has also been shown to be very well tolerated." | 2.38 | A review of the antiarthritic efficacy and safety of etodolac. ( Zvaifler, N, 1989) |
| "Etodolac is a new non-steroidal agent (NSAID) with anti-inflammatory and analgesic activity." | 2.37 | Etodolac. A preliminary review of its pharmacodynamic activity and therapeutic use. ( Brogden, RN; Lynch, S, 1986) |
| " The pharmacokinetic study in human volunteers showed that the selected etodolac-loaded cubosomes enhanced the bioavailability of etodolac as compared to the oral capsules (266." | 1.46 | Etodolac transdermal cubosomes for the treatment of rheumatoid arthritis: ex vivo permeation and in vivo pharmacokinetic studies. ( Kamel, AO; Mahmoud, AA; Salah, S, 2017) |
| "This is the first case report of membranous nephropathy in a patient with early-stage rheumatoid arthritis treated with the relatively selective cyclooxygenase-2 inhibitor, etodolac." | 1.34 | Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. ( Aoyama, M; Deji, N; Kashiwagi, A; Kikuchi, K; Nishio, Y; Sakaguchi, M; Sugimoto, T; Uzu, T, 2007) |
| " No differences in the half-life of etodolac elimination were noted." | 1.27 | The pharmacokinetics of etodolac in serum and synovial fluid of patients with arthritis. ( Furst, D; Furst, J; Hicks, DR; Kraml, M; McKean, M; Panagides, J, 1988) |
| "Etodolac-low dose was significantly more effective than placebo in nine of ten clinical assessments and in all ten at high dose." | 1.26 | Comparative efficacy of etodolac and placebo in rheumatoid arthritic patients. ( Joubert, L; Placchi, M; Vetter, G, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (41.30) | 18.7374 |
| 1990's | 21 (45.65) | 18.2507 |
| 2000's | 4 (8.70) | 29.6817 |
| 2010's | 2 (4.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asselin, AA | 1 |
| Humber, LG | 2 |
| Dobson, TA | 1 |
| Komlossy, J | 1 |
| Martel, RR | 1 |
| Demerson, CA | 1 |
| Philipp, AH | 1 |
| Salah, S | 1 |
| Mahmoud, AA | 1 |
| Kamel, AO | 1 |
| Mehta, P | 1 |
| Lukacs, M | 1 |
| Abraham, SM | 1 |
| Paulus, HE | 2 |
| Di Primeo, D | 2 |
| Sharp, JT | 2 |
| Genant, HK | 2 |
| Weissman, BN | 2 |
| Weisman, MH | 1 |
| Sanda, M | 5 |
| Tanaka, H | 1 |
| Abe, T | 1 |
| Nishimura, S | 1 |
| Sakai, H | 1 |
| Kimura, H | 1 |
| Oki, M | 1 |
| Nojima, M | 1 |
| Taga, M | 1 |
| Matsumoto, S | 1 |
| Takahashi, H | 1 |
| Imai, K | 1 |
| Sugimoto, T | 1 |
| Aoyama, M | 1 |
| Kikuchi, K | 1 |
| Sakaguchi, M | 1 |
| Deji, N | 1 |
| Uzu, T | 1 |
| Nishio, Y | 1 |
| Kashiwagi, A | 1 |
| Vetter, G | 1 |
| Placchi, M | 1 |
| Joubert, L | 1 |
| del Toro, RA | 1 |
| Concepción, R | 1 |
| Edwards, W | 1 |
| Bacon, PA | 2 |
| Veys, EM | 1 |
| Cummings, DM | 1 |
| Amadio, P | 1 |
| Anaya, JM | 1 |
| Fabre, D | 1 |
| Bressolle, F | 1 |
| Bologna, C | 1 |
| Alric, R | 1 |
| Cocciglio, M | 1 |
| Dropsy, R | 1 |
| Sany, J | 1 |
| Dreiser, RL | 1 |
| Porzio, F | 1 |
| Schattenkirchner, M | 2 |
| Lonauer, G | 1 |
| Tisscher, JR | 1 |
| Lim, HG | 1 |
| Bijlsma, JW | 1 |
| Spencer-Green, G | 1 |
| Lightfoot, R | 1 |
| Neustadt, DH | 1 |
| Matsunaga, K | 1 |
| Yawata, M | 1 |
| Hagiya, N | 1 |
| Tani, K | 1 |
| Kawai, T | 1 |
| Nagaoka, S | 1 |
| Aoki, A | 1 |
| Nakamura, M | 1 |
| Senuma, A | 1 |
| Motoji, K | 1 |
| Chiba, J | 1 |
| Ishigatsubo, Y | 1 |
| Lynch, JM | 1 |
| Schwartz, BA | 1 |
| Balfour, JA | 1 |
| Buckley, MM | 1 |
| Bianchi Porro, G | 1 |
| Caruso, I | 1 |
| Petrillo, M | 1 |
| Montrone, F | 1 |
| Ardizzone, S | 1 |
| Taha, AS | 2 |
| McLaughlin, S | 2 |
| Holland, PJ | 1 |
| Kelly, RW | 1 |
| Sturrock, RD | 2 |
| Russell, RI | 3 |
| Serni, U | 1 |
| Benhamou, CL | 1 |
| Puccetti, L | 2 |
| Soletti, A | 1 |
| Petrini, G | 1 |
| Remorini, E | 2 |
| Zuccotti, M | 1 |
| Bazzichi, L | 2 |
| Ciompi, ML | 2 |
| Zvaifler, N | 1 |
| Briancon, D | 1 |
| Karbowski, A | 1 |
| Marotta, G | 1 |
| Gospodinoff, A | 1 |
| Fiore, L | 1 |
| Dardano, B | 1 |
| Fiore, D | 1 |
| Scapato, P | 1 |
| Jacob, G | 1 |
| Messina, M | 1 |
| Kennedy, J | 1 |
| Epstein, C | 2 |
| Mullane, J | 1 |
| Shand, DG | 1 |
| Kinberg-Calhoun, J | 1 |
| Mullane, JF | 2 |
| Lynch, S | 1 |
| Brogden, RN | 1 |
| Jallad, NS | 1 |
| Salom, IL | 1 |
| Perdomo, CS | 1 |
| Garg, DC | 1 |
| Weidler, DJ | 1 |
| Waltham-Weeks, CD | 1 |
| Wooley, PH | 1 |
| Whalen, JD | 1 |
| Zimmerman, JL | 1 |
| Champion, TM | 1 |
| Kraml, M | 1 |
| Hicks, DR | 1 |
| McKean, M | 1 |
| Panagides, J | 1 |
| Furst, D | 1 |
| Furst, J | 1 |
9 reviews available for etodolac and Rheumatoid Arthritis
| Article | Year |
|---|---|
[A case of rheumatoid arthritis/Sjogren's syndrome with acute renal failure due to hyperuricemia associated with mizoribine therapy].
Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Therapy, C | 2004 |
Clinical performance of etodolac in patients with osteoarthritis and rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Etodolac; | 1994 |
A review of selected newer nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Clinical Trials as Topic; | 1994 |
Meta-analysis of two double-blind comparative studies with the sustained-release form of etodolac in rheumatoid arthritis.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Delayed-Action Prepa | 1993 |
Low dose etodolac in rheumatoid arthritis: a review of early studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Etodolac; Humans | 1997 |
Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Etodolac; Humans; Indoleace | 1991 |
A review of the antiarthritic efficacy and safety of etodolac.
Topics: Activities of Daily Living; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Binding, | 1989 |
A global safety evaluation of etodolac.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tr | 1989 |
Etodolac. A preliminary review of its pharmacodynamic activity and therapeutic use.
Topics: Acetates; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Etodolac; Humans; | 1986 |
27 trials available for etodolac and Rheumatoid Arthritis
| Article | Year |
|---|---|
Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2004 |
Twelve-week study of etodolac, aspirin, and placebo in patients with rheumatoid arthritis.
Topics: Acetates; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as | 1983 |
Etodolac, aspirin, and placebo in patients with rheumatoid arthritis: a 12-week study.
Topics: Acetates; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as | 1983 |
Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Proteins; Drug Interactions; Etodolac; Female; Humans; Mal | 1994 |
A comparison of the efficacy of etodolac SR (Lodine SR) and etodolac (Lodine) in patients with rheumatoid arthritis or osteoarthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Delayed-Action Preparations; Dose-Response Relationship, Drug; D | 1993 |
The safety profile of sustained-release etodolac.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Delayed-Action Preparations; Dose-Response Relation | 1993 |
Double-blind comparison of etodolac and diclofenac in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Diclofenac; Etodolac; Female; Humans; Male; Middle A | 1993 |
Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. Etodolac Study 326 Rheumatoid Arthritis Investigators Group.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Respon | 1997 |
Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Disease Progression; Double-B | 1997 |
[Investigation of plasma levels of etodolac and urine PGE2 in patients with rheumatoid arthritis].
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dinoproston | 1999 |
Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Arthrography; Disease Progression; Dose-Response Rel | 2000 |
A double-blind gastroscopic evaluation of the effects of etodolac and naproxen on the gastrointestinal mucosa of rheumatic patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Double-Blind Method; Etodolac; Femal | 1991 |
Double-blind comparison of etodolac and piroxicam in patients with rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Double-Blind Method; Et | 1991 |
Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tr | 1990 |
An overview of the efficacy of etodolac in arthritic disorders.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; | 1990 |
Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dinoproston | 1990 |
Large-scale open trials with etodolac (Lodine) in France: an assessment of safety.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response Rel | 1990 |
Effectiveness and safety of etodolac in treatment of rheumatoid arthritis: a multicentre two-months' open study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Etodolac; Female; Human | 1990 |
Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Double-Blind Method; Dr | 1989 |
International experience with etodolac therapy for rheumatoid arthritis: an interim report of comparative efficacy.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; | 1989 |
A global safety evaluation of etodolac.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tr | 1989 |
Etodolac versus diclofenac: double-blind cross-over study in rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Sedimentation; Clinical | 1989 |
Minimum effective dose of etodolac for the treatment of rheumatoid arthritis.
Topics: Acetates; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rhe | 1986 |
The effect of etodolac administration on renal function in patients with arthritis.
Topics: Acetates; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Blood Urea | 1986 |
Gastrointestinal blood loss in arthritic patients receiving chronic dosing with etodolac and piroxicam.
Topics: Acetates; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response | 1986 |
Etodolac--a new NSAID for rheumatoid arthritis.
Topics: Acetates; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Double-Blind Method; Etodolac; H | 1987 |
Etodolac versus naproxen in rheumatoid arthritis: a double-blind crossover study.
Topics: Acetates; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Double-Blind | 1987 |
11 other studies available for etodolac and Rheumatoid Arthritis
| Article | Year |
|---|---|
Cycloalkanoindoles. 1. Syntheses and antiinflammatory actions of some acidic tetrahydrocarbazoles, cyclopentindoles, and cycloheptindoles.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Carbazoles; Cycloheptanes; Cyclopentanes; | 1976 |
Etodolic acid and related compounds. Chemistry and antiinflammatory actions of some potent di- and trisubstituted 1, 3, 4, 9-tetrahydropyrano[3, 4-b]indole-1-acetic acids.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Carrageenan; Freund's Adjuvant; Indoleacet | 1976 |
Etodolac transdermal cubosomes for the treatment of rheumatoid arthritis: ex vivo permeation and in vivo pharmacokinetic studies.
Topics: Administration, Cutaneous; Animals; Arthritis, Rheumatoid; Drug Liberation; Etodolac; Humans; Partic | 2017 |
Normal in the blood, abnormal in the urine.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Bilirubi | 2012 |
Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biopsy, Needle; Cyclooxygenase 2 Inhibitors; Etodolac; Female; Follow-Up Stud | 2007 |
Comparative efficacy of etodolac and placebo in rheumatoid arthritic patients.
Topics: Acetates; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response Relati | 1982 |
Safety profile of etodolac in the elderly population.
Topics: Age Factors; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Delayed-Action Preparations; Dic | 1994 |
Global safety of etodolac: reports from worldwide postmarketing surveillance studies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 1990 |
[Open clinical study on the efficacy and tolerance of acemetacin in rheumatoid arthritis and osteoarthrosis].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Etodolac; Female; Human | 1989 |
The effect of etodolac on type II collagen-induced arthritis in mice.
Topics: Acetates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Collagen; Etodola | 1987 |
The pharmacokinetics of etodolac in serum and synovial fluid of patients with arthritis.
Topics: Acetates; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Etodolac; Fem | 1988 |